Fairfield, Bush & Co. Nektar Therapeutics Transaction History

Fairfield, Bush & Co.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 06, 2022	BUY	$4.16 - $13.72 $832 - $2,744	200 New	200 $1,000
Q2 2020 Aug 13, 2020	SELL	$16.86 - $23.44 $205,692 - $285,968	-12,200 Closed	0 $0
Q1 2020 May 13, 2020	SELL	$14.47 - $27.96 $5,788 - $11,184	-400 Reduced 3.17%	12,200 $218,000
Q4 2019 Feb 12, 2020	SELL	$15.87 - $23.12 $7,935 - $11,560	-500 Reduced 3.82%	12,600 $272,000
Q3 2019 Nov 13, 2019	SELL	$16.91 - $36.27 $16,910 - $36,270	-1,000 Reduced 7.09%	13,100 $239,000

Q1 2019 May 15, 2019	BUY	$31.58 - $46.35 $66,318 - $97,335	2,100 Added 17.5%	14,100 $474,000
Q3 2017 Nov 14, 2017	BUY	$17.79 - $24.0 $213,480 - $288,000	12,000	12,000 $288,000

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $219M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Fairfield, Bush & Co., based on Form 13F filings with the SEC.

Stay updated on Fairfield, Bush & Co. with notifications on news.